109 related articles for article (PubMed ID: 2500234)
1. Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer.
Abbruzzese JL; Levin B; Ajani JA; Faintuch JS; Saks S; Patt YZ; Edwards C; Ende K; Gutterman JU
Cancer Res; 1989 Jul; 49(14):4057-61. PubMed ID: 2500234
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of recombinant human interferon-gamma and recombinant tumor necrosis factor in patients with advanced gastrointestinal malignancies: results of a trial terminated by excessive toxicity.
Abbruzzese JL; Levin B; Ajani JA; Faintuch JS; Pazdur R; Saks S; Edwards C; Gutterman JU
J Biol Response Mod; 1990 Oct; 9(5):522-7. PubMed ID: 2123922
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose-escalation study of tumor necrosis factor-alpha and concomitant radiation therapy.
Hallahan DE; Vokes EE; Rubin SJ; O'Brien S; Samuels B; Vijaykumar S; Kufe DW; Phillips R; Weichselbaum RR
Cancer J Sci Am; 1995; 1(3):204-9. PubMed ID: 9166477
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon: toxicity, monocytosis, and clinical effects.
Weiner LM; Li W; Holmes M; Catalano RB; Dovnarsky M; Padavic K; Alpaugh RK
Cancer Res; 1994 Aug; 54(15):4084-90. PubMed ID: 8033141
[TBL] [Abstract][Full Text] [Related]
5. A phase I/II study of recombinant tumor necrosis factor and recombinant interferon gamma in patients with AIDS-related complex.
Kaplan LD; Abrams DI; Sherwin SA; Kahn J; Volberding PA
Biotechnol Ther; 1989-1990; 1(3):229-36. PubMed ID: 2562651
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma.
Lenzi R; Rosenblum M; Verschraegen C; Kudelka AP; Kavanagh JJ; Hicks ME; Lang EA; Nash MA; Levy LB; Garcia ME; Platsoucas CD; Abbruzzese JL; Freedman RS
Clin Cancer Res; 2002 Dec; 8(12):3686-95. PubMed ID: 12473577
[TBL] [Abstract][Full Text] [Related]
7. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
8. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
Budd GT; Osgood B; Barna B; Boyett JM; Finke J; Medendorp SV; Murthy S; Novak C; Sergi J; Tubbs R
Cancer Res; 1989 Nov; 49(22):6432-6. PubMed ID: 2804986
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
11. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B.
Musch E; Högemann B; Gerritzen A; Fischer HP; Wiese M; Kruis W; Malek M; Gugler R; Schmidt G; Huchzermeyer H; Gerlach U; Dengler HJ; Sauerbruch T
Hepatogastroenterology; 1998; 45(24):2282-94. PubMed ID: 9951911
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of recombinant human tumor necrosis factor-alpha in patients with advanced malignancies.
Bartsch HH; Nagel GA; Mull R; Flener R; Pfizenmaier K
Mol Biother; 1988; 1(1):21-9. PubMed ID: 3267369
[TBL] [Abstract][Full Text] [Related]
13. Effects of monoclonal antibody, recombinant interferon-gamma, and tumor necrosis factor-alpha in the treatment of human melanoma xenografts.
Gridley DS; Slater JM; Stickney DR
J Biol Response Mod; 1989 Dec; 8(6):593-602. PubMed ID: 2513378
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor in advanced gastrointestinal neoplasms. A clinical trial with a focus on haematological effects.
Muc-Wierzgoń M; Baranowski M; Madej K
Haematologia (Budap); 1996; 27(2):85-92. PubMed ID: 14651225
[TBL] [Abstract][Full Text] [Related]
15. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions.
Safdar A; Rodriguez GH; Lichtiger B; Dickey BF; Kontoyiannis DP; Freireich EJ; Shpall EJ; Raad II; Kantarjian HM; Champlin RE
Cancer; 2006 Jun; 106(12):2664-71. PubMed ID: 16691620
[TBL] [Abstract][Full Text] [Related]
16. Effects of MAb BW 494/32 and rTNF-a/rIFN-g alone and in combination in nude mice bearing xenografts of human gastrointestinal/pancreatic carcinomas.
Klapdor R; Schwarzenberg O; Kühl JS; Franke N; Bahlo M
Strahlenther Onkol; 1989 Jul; 165(7):549-50. PubMed ID: 2501886
[No Abstract] [Full Text] [Related]
17. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of recombinant human tumor necrosis factor in colorectal carcinoma.
Schaadt M; Pfreundschuh M; Lorscheidt G; Peters KM; Steinmetz T; Diehl V
J Biol Response Mod; 1990 Apr; 9(2):247-50. PubMed ID: 2341863
[TBL] [Abstract][Full Text] [Related]
19. A dose-escalation and pharmacokinetic study of subcutaneously administered recombinant human interleukin 12 and its biological effects in Japanese patients with advanced malignancies.
Ohno R; Yamaguchi Y; Toge T; Kinouchi T; Kotake T; Shibata M; Kiyohara Y; Ikeda S; Fukui I; Gohchi A; Sugiyama Y; Saji S; Hazama S; Oka M; Ohnishi K; Ohhashi Y; Tsukagoshi S; Taguchi T
Clin Cancer Res; 2000 Jul; 6(7):2661-9. PubMed ID: 10914707
[TBL] [Abstract][Full Text] [Related]
20. Synergistic enhancement of the antitumor activity of recombinant human TNF-alpha by recombinant human IFN-gamma.
Taguchi T; Abe S; Nakano K; Matsui Y; Sohmura Y
Cancer Detect Prev; 1988; 12(1-6):105-14. PubMed ID: 3141050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
